Adamas Announces New Employment Inducement Grant
09 mai 2018 16h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas Reports First Quarter 2018 Financial Results
03 mai 2018 16h05 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S....
Adamas to Present at Two Upcoming Investor Conferences
02 mai 2018 15h22 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences: ...
Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018
26 avr. 2018 16h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May...
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
19 avr. 2018 05h30 HE
|
Adamas Pharmaceuticals, Inc.
-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif.,...
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
12 avr. 2018 17h09 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced it will make six data presentations at the 70th Annual Meeting of the American...
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
03 avr. 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial of...
Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
15 mars 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules for the...
Adamas to Present at Two Upcoming Investor Conferences
06 mars 2018 14h35 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor...
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
22 févr. 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended...